Difference between revisions of "Ber-EP4"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
'''Ber-EP4''' is a commonly available [[immunostain]]. | '''Ber-EP4''' is a commonly available [[immunostain]]. It is directed against EpCam.<ref name=pmid24179394>{{Cite journal | last1 = Dasgeb | first1 = B. | last2 = Mohammadi | first2 = TM. | last3 = Mehregan | first3 = DR. | title = Use of Ber-EP4 and Epithelial Specific Antigen to Differentiate Clinical Simulators of Basal Cell Carcinoma. | journal = Biomark Cancer | volume = 5 | issue = | pages = 7-11 | month = | year = 2013 | doi = 10.4137/BIC.S11856 | PMID = 24179394 }}</ref> | ||
==Positive== | ==Positive== | ||
Revision as of 16:29, 15 May 2016
Ber-EP4 is a commonly available immunostain. It is directed against EpCam.[1]
Positive
- Basal cell carcinoma.
- Lung adenocarcinoma (55 of 59 cases[2]).
Negative
- Squamous cell carcinoma of the skin.[3]
- Malignant mesothelioma (18 of 70 cases[2]).
- Microcystic adnexal carcinoma.[4]
See also
References
- ↑ Dasgeb, B.; Mohammadi, TM.; Mehregan, DR. (2013). "Use of Ber-EP4 and Epithelial Specific Antigen to Differentiate Clinical Simulators of Basal Cell Carcinoma.". Biomark Cancer 5: 7-11. doi:10.4137/BIC.S11856. PMID 24179394.
- ↑ 2.0 2.1 Ordóñez, NG. (Jan 1998). "Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.". Am J Clin Pathol 109 (1): 85-9. PMID 9426522.
- ↑ Yu, L.; Galan, A.; McNiff, JM. (Oct 2009). "Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma.". J Cutan Pathol 36 (10): 1074-176. doi:10.1111/j.1600-0560.2008.01223.x. PMID 19187107.
- ↑ Sellheyer, K.; Nelson, P.; Kutzner, H.; Patel, RM. (Apr 2013). "The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers.". J Cutan Pathol 40 (4): 363-70. doi:10.1111/cup.12085. PMID 23398472.